What is Roth Capital’s Forecast for ChromaDex Q4 Earnings?

ChromaDex Co. (NASDAQ:CDXC) – Roth Capital lowered their Q4 2024 EPS estimates for shares of ChromaDex in a note issued to investors on Tuesday, November 5th. Roth Capital analyst S. Mcgowan now forecasts that the company will post earnings per share of $0.00 for the quarter, down from their previous forecast of $0.01. The consensus estimate for ChromaDex’s current full-year earnings is $0.01 per share. Roth Capital also issued estimates for ChromaDex’s FY2025 earnings at $0.05 EPS and Q3 2026 earnings at $0.05 EPS.

A number of other research analysts also recently issued reports on CDXC. HC Wainwright boosted their price target on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday. Roth Mkm boosted their price target on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday.

ChromaDex Price Performance

NASDAQ:CDXC opened at $6.99 on Thursday. The firm’s 50 day simple moving average is $3.70 and its 200 day simple moving average is $3.28. ChromaDex has a one year low of $1.32 and a one year high of $7.08. The company has a market cap of $530.77 million, a PE ratio of 699.00 and a beta of 1.88.

ChromaDex (NASDAQ:CDXC) last posted its earnings results on Thursday, October 31st. The company reported $0.02 EPS for the quarter. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. The business had revenue of $25.58 million for the quarter, compared to the consensus estimate of $23.70 million. During the same period last year, the company earned ($0.01) EPS.

Institutional Investors Weigh In On ChromaDex

Hedge funds have recently added to or reduced their stakes in the company. OneDigital Investment Advisors LLC lifted its holdings in shares of ChromaDex by 5.5% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 59,414 shares of the company’s stock worth $217,000 after purchasing an additional 3,097 shares in the last quarter. Miracle Mile Advisors LLC bought a new position in ChromaDex in the 2nd quarter valued at about $27,000. The Manufacturers Life Insurance Company acquired a new position in ChromaDex during the 2nd quarter valued at about $31,000. Merriman Wealth Management LLC bought a new stake in ChromaDex during the 2nd quarter worth approximately $32,000. Finally, Lazard Asset Management LLC purchased a new stake in shares of ChromaDex in the first quarter worth approximately $43,000. Institutional investors and hedge funds own 15.41% of the company’s stock.

Insider Transactions at ChromaDex

In other news, Director Kristin Patrick sold 23,000 shares of ChromaDex stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $3.57, for a total value of $82,110.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 9.64% of the company’s stock.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.